AEOL 11114

Drug Profile

AEOL 11114

Alternative Names: AEOL 11114B; AEOL11114

Latest Information Update: 18 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Jewish Medical and Research Center; University of Colorado at Anschutz Medical Campus
  • Class Antiparkinsonians; Glyoxylates; Metalloporphyrins; Porphyrins
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 31 Mar 2016 Aeolus receives patent allowance for AAEOL 11114 in Japan prior to March 2016
  • 02 Nov 2015 AEOL 11114 licensed to Aeolus worldwide for the treatment of Parkinson's disease
  • 02 Nov 2015 Aeolus receives patent allowance for AAEOL 11114 in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top